CDXS Key Statistics, Chart & Performance
The current stock price of CDXS is 1.68 USD. In the past month the price decreased by -9.89%. In the past year, price decreased by -62.64%.
CDXS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 27.48 | 231.23B | ||
| DHR | DANAHER CORP | 31 | 168.82B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 203.38 | 61.80B | ||
| A | AGILENT TECHNOLOGIES INC | 26.52 | 41.96B | ||
| IQV | IQVIA HOLDINGS INC | 20.71 | 41.02B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 35.66 | 30.48B | ||
| WAT | WATERS CORP | 31 | 23.44B | ||
| ILMN | ILLUMINA INC | 33.38 | 22.24B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 38.6 | 19.63B | ||
| MEDP | MEDPACE HOLDINGS INC | 41.9 | 16.88B | ||
| RVTY | REVVITY INC | 21.69 | 11.78B | ||
| TEM | TEMPUS AI INC | N/A | 12.32B |
Related stock screener links
About CDXS
Company Profile
Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. The company is headquartered in Redwood City, California and currently employs 188 full-time employees. The company went IPO on 2010-04-22. The company is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high-performance enzymes and other classes of proteins. The firm utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. The company is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) and other RNA-based therapeutics through an enzymatic route. The firm also uses the CodeEvolver platform technology to develop enzymes for the synthesis of RNAi therapeutics through its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.
Company Info
CODEXIS INC
200 Penobscot Dr
Redwood City CALIFORNIA 94063 US
CEO: John J. Nicols
Employees: 188
Phone: 16504218100
CODEXIS INC / CDXS FAQ
Can you describe the business of CODEXIS INC?
Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. The company is headquartered in Redwood City, California and currently employs 188 full-time employees. The company went IPO on 2010-04-22. The company is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high-performance enzymes and other classes of proteins. The firm utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. The company is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) and other RNA-based therapeutics through an enzymatic route. The firm also uses the CodeEvolver platform technology to develop enzymes for the synthesis of RNAi therapeutics through its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.
What is the current price of CDXS stock?
The current stock price of CDXS is 1.68 USD. The price increased by 2.44% in the last trading session.
What is the dividend status of CODEXIS INC?
CDXS does not pay a dividend.
What is the ChartMill technical and fundamental rating of CDXS stock?
CDXS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Should I buy CDXS stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CDXS.
What is the expected growth for CDXS stock?
The Revenue of CODEXIS INC (CDXS) is expected to grow by 3.05% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
CDXS Technical Analysis
CDXS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CDXS. CDXS may be in some trouble as it scores bad on both profitability and health.
CDXS Financial Highlights
Over the last trailing twelve months CDXS reported a non-GAAP Earnings per Share(EPS) of -0.76. The EPS increased by 12.64% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -51.59% | ||
| ROE | -165.92% | ||
| Debt/Equity | 1.03 |
CDXS Forecast & Estimates
13 analysts have analysed CDXS and the average price target is 6.71 USD. This implies a price increase of 299.7% is expected in the next year compared to the current price of 1.68.
For the next year, analysts expect an EPS growth of 25.65% and a revenue growth 3.05% for CDXS